Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Ellen Matloff on Oophorectomy Timing for BRCA Carriers

March 10th 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Preventative Ovarian Surgery in BRCA1 Mutation Carriers More Beneficial Before Age 35

February 24th 2014

For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.

Dr. Monk on Trial Endpoints For Ovarian Cancer Agents

February 17th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, on clinical trial endpoints and the approval of agents for ovarian cancer.

Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers

January 17th 2014

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

FDA Rules Hamper Novel Ovarian Cancer Drugs

January 7th 2014

The FDA's rules for approving new drugs for the treatment of women with ovarian cancer pose frustrating problems for researchers developing novel agents and for clinicians seeking to improve outcomes for their patients

Dr. Muggia on Doxil in Ovarian Cancer

January 7th 2014

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses using Doxil to treat ovarian cancer.

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

January 3rd 2014

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment

January 3rd 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

PARP Inhibitors Reemerge as Treatment for Serous Ovarian Cancer

December 31st 2013

The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target which can be exploited through the use of PARP inhibitors

Dr. Monk Discusses the TRINOVA-1 Trial

November 20th 2013

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

Dr. Muggia on Targeted Therapies in Ovarian Cancer

November 14th 2013

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Dr. Morgan on Bulk Reduction Surgery in Ovarian Cancer

November 6th 2013

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Dr. Burger on Bevacizumab Toxicity in Ovarian Cancer

November 1st 2013

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.

Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDA

October 29th 2013

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

October 25th 2013

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses the role of PARP inhibitors in ovarian cancer.

Dr. Schilder on PARP Inhibitors in Gynecologic Cancers

October 22nd 2013

Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.

Nanotech system, cellular heating may improve treatment of ovarian cancer

October 17th 2013

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs.

Dr. Birrer on the Approval Process in Ovarian Cancer

October 16th 2013

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, explains how the endpoints of progression-free survival (PFS) and overall survival (OS) are holding back the approval of drugs for patients with ovarian cancer.

Dr. Morgan on Robotic Surgery in Gynecologic Cancer

October 11th 2013